https://www.selleckchem.com/pr....oducts/tenalisib-rp6
In agreement with the proposed mechanism of late action, celgosivir was active against DENV only in the secondary YRA (IC50 11.0 ± 1.0 µM) and in PRA (IC50 10.1 ± 1.1 µM). The assay format overcomes relevant limitations of the gold standard PRA, allowing concurrent analysis of candidate antiviral compounds against different viruses and providing preliminary information about early versus late antiviral activity.Introduction Psychological issues are common in patients with chronic disabling diseases such as asthma. National guid
Like
Comment
Share
